Compare Novo Nordisk A/S (NVO) vs Raytheon Technologies Corp (RTX) Price & Performance

Novo Nordisk A/STrade

Raytheon Technologies CorpTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Raytheon Technologies Corp — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Raytheon Technologies Corp trades at $193.75 (market cap $261.85B). The key difference: Raytheon Technologies Corp is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.

	NVO	RTX
Market Cap	$220.53B	$261.85B
Sector	Health	Industrials
52-Week High	$71.70	$212.16
52-Week Low	$35.29	$149.17
Enterprise Value	$239.49B	$293.97B
Dividend Yield	3.63%	1.5%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

No Aura AI signal available yet.

Raytheon Technologies Corp

RTX trades at $193.51, down 0.44% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar deal (PRNewsWire, June 3, 2026), and earnings beats in Q4 2025 and Q1 2026 highlight operational momentum. Revenue growth accelerated to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock faces resistance near $196-$199, with support at $192.

The outlook remains positive given defense spending tailwinds and production expansions, but elevated P/E of 36.48 poses valuation risk. Analysts project 10% upside to a $213 consensus target, with no sell ratings. Key risks include debt levels and geopolitical volatility affecting contracts.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 10 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 14 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

RTX

OpenAI and Anthropic boost lobbying to $3.17M in Q2 ahead of IPOs and midtermsCNBC · 9 hours agoNeutral Collins Aerospace and Etihad Engineering form JV to expand aircraft MRO services in Abu Dhabi.PRNewsWire · 10 hours agoBullish Tigerair Taiwan orders 15 Airbus A321neos with fuel-efficient Pratt & Whitney GTF engines.PRNewsWire · 11 hours agoBullish View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.